ENT Cancer Clinical Trial
— TADDOROfficial title:
Randomized, Double Blind, Efficacy Study of Escitalopram Versus Placebo in ENT Cancer Patients Suffering From Emotional Distress
Escitalopram is an antidepressant inhibitor of the serotonin reuptake. On the market in
France since 2002.
Prevalence of emotional distress in patients with cancer is 30-50%. this prevalence may vary
regarding the tumor localisation, the population, intensity of the symptoms...
Incidence of ENT cancer is highly significant in France, it is one of the most important in
the world 37 out of 100 000. it is in patients with ENT cancer that the prevalence of
depression is the most important (22%-57%).
Researches appears necessary to assessed the efficacy of antidepressant treatments with as
primary objective not only the decrease of depressive symptoms but also an ensemble of
physic and psychological symptoms.
| Status | Completed |
| Enrollment | 38 |
| Est. completion date | March 2013 |
| Est. primary completion date | March 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Patients with ENT cancer of stage I to IVb that have to go under surgery and/or radiotherapy and/or chemotherapy as first line treatment. It may be a primary cancer or a new localisation. - Total score on HADS scale >11 - Patients aged from 18 to 75 years - Signed informed consent - OMS < 2, hospitalized or ambulatory - Are authorized to inclusion, psychoactive treatments at stable dosage for two weeks for benzodiazepins, neuroleptics, antihistaminics or other anxiolytics or hypnotics Exclusion Criteria: - Patients in palliative treatments - Previous bipolar disorder or schizophrenia - Major depressive episode with severity criteria - Suicidal patients - Acute infection - ASAT/ALAT >3N - Creatinine clearance <30 ml/mn - Natremia inferior to the laboratory standard - For alcoholic patients non abstinent at the time of inclusion, previous "delirium tremens" - Previous upper gist bleeding - Inefficacy or intolerance of previous treatment by escitalopram - Not compatible concomitant treatment: - Other antidepressive than escitalopram (except clonazepam) - all hypnotics (except zolpidem) - all anxiolytics (except clonazepam, clorazepate and diazepam) - medical treatment for smoking addiction like bupropion or varenicline - Pregnant or breastfeeding women - Patients under guardianship - Patients without insurance - Impossibility to follow the protocol for geographical, social or psychic reasons - Insufficient knowledge of French |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| France | Gustave Roussy | Villejuif | Val de Marne |
| Lead Sponsor | Collaborator |
|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Efficacy of treatment by Escitalopram on depressive symptoms | Assessed using HADS scale | Assessed 3 months after randomization | No |
| Secondary | Efficacy of treatment on emotional distress | Assessed using HADS scale | Assessed 3 months after randomization | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|